Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Solasia Pharma KK's PEG Ratio or its related term are showing as below:
TSE:4597's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.665 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Solasia Pharma KK (TSE:4597) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Solasia Pharma KK PEG Ratio Related Terms
Solasia Pharma KK PEG Ratio Historical Data
* Premium members only.
The historical data trend for Solasia Pharma KK's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasia Pharma KK PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Solasia Pharma KK's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Solasia Pharma KK (TSE:4597) has a PEG Ratio of 0.00 as of Jul. 13, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Solasia Pharma KK and its competitors. According to the industry distribution chart, Solasia Pharma KK ranks #999999 out of 348 companies in the Drug Manufacturers industry.
Is Solasia Pharma KK's PEG Ratio too high?
Solasia Pharma KK's current PEG Ratio is 0.00. Based on the distribution chart, Solasia Pharma KK ranks #999999 out of 348 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Solasia Pharma KK has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Solasia Pharma KK ranks #999999 out of 348 companies for PEG Ratio. This places Solasia Pharma KK in the lower half of its industry. The industry median PEG Ratio is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.67, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Solasia Pharma KK and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasia Pharma KK's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (TSE:4597) is currently considered Significantly Overvalued. The stock's GF Value™ is 円2.42, compared to a current price of 円27.00 — trading 1015.7% above its estimated fair value. The current PEG Ratio is 0.00. Solasia Pharma KK's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Solasia Pharma KK (TSE:4597), the current PEG Ratio is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasia Pharma KK (TSE:4597) Overvalued in 2026?
Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued.
The current stock price of 円27.00 is trading 1015.7% above its estimated GF Value™ of 円2.42.
GuruFocus considers Solasia Pharma KK to be Significantly Overvalued.
Key valuation signals for TSE:4597:
PEG Ratio: 0.00
GF Value™: 円2.42 vs. price of 円27.00 (1015.7% above fair value)
No single metric tells the full story. See the TSE:4597 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4597 has been successfully added to your 
